C12N 2710/10241
Use of virus, viral particle or viral elements as a vector
C12N2710/10241 (Use of virus, viral particle or viral elements as a vector) appears on 18 US grants and 18 published applications in this corpus.
Search patents in C12N- Granted patents
- 18
- Published applications
- 18
- Assignees
- 19
- Inventors
- 60
- Latest grant
- 15 Oct 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 2 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 3 | 0 |
| 2002 | 1 | 2 |
| 2003 | 1 | 1 |
| 2004 | 3 | 1 |
| 2005 | 1 | 2 |
| 2006 | 0 | 1 |
| 2007 | 1 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 0 |
| 2011 | 1 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 1 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 1 |
| 2019 | 0 | 1 |
| 2020 | 1 | 2 |
| 2021 | 0 | 1 |
| 2022 | 0 | 1 |
| 2023 | 0 | 1 |
| 2024 | 1 | 1 |
| 2025 | 0 | 1 |
By publication year. Applications have been published since 2001.
Subgroups
Granted patents
- C12N 2710/10243Viral genome or elements thereof as genetic vectorIndexing code18
- C12N 2710/10242Virus or viral particle as vehicleIndexing code0
- C12N 2710/10244Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code0
- C12N 2710/10245Special targeting system for viral vectorsIndexing code0
Recent patents
- Codon-optimized human NPC1 genes for the treatment of Niemann-Pick type C1 deficiency and related conditions15 Oct 2024US 12,116,577 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Vaccine in the form of a recombinant sero type 9 avian adenovirus vector1 Sep 2020US 10,758,608 B2Grupo Industrial Pecuario, S.A. De C.V.
- Non-pathogenic serotype 4 fowl adenovirus (fadv-4) and viral vector thereof1 Sep 2015US 9,119,834 B2University of Guelph
- Recombinant adenoviral vectors and their utility in the treatment of various types of fibrosis: hepatic, renal, pulmonary, as well as hypertrophic scars25 Oct 2011US 8,043,855 B2TGT Laboratories, S.A. DE C.V.
- Recombinant adenoviral vectors and their utility in the treatment of various types of fibrosis: hepatic, renal, pulmonary, as well as hypertrophic scars28 Dec 2010US 7,858,368 B2TGT Laboratories, S.A. DE C.V.
- Fusion proteins against sialosylated glycosphingolipids and sialated glycoproteins and uses thereof20 Nov 2025US 2025/0353901 A1On. Target Molecules Biotech Inc.
- Codon-optimized human npc1 genes for the treatment of niemann-pick type c1 deficiency and related conditions12 Dec 2024US 2024/0409948 A1The United States of America, as represented by the Secretary, Department of Health and Human Services
- Replication-deficient avian adenoviral vectors, their design and uses11 May 2023US 2023/0140994 A1Greffex, Inc.
- Improved production of recombinant aav using embryonated avian eggs29 Sep 2022US 2022/0307055 A1University of Florida Research Foundation, Inc.
- Fowl adenovirus 9 (fadv-9) vector system and associated methods14 Oct 2021US 2021/0317476 A1University of Guelph
Most cited
By later US patents
- Immortalized human cell lines containing exogenous cytochrome P450 genes17US 5,506,131 AThe United States of America as represented by the Department of Health and Human Services · 1996
- Modified hepatocytes and uses therefor15US 5,521,076 AHoward Hughes Medical Center · 1996
- Defective recombinant adenoviruses expressing cytokines for antitumor treatment13US 6,811,774 B2Centre National De La Recherche Scientifique · 2004
- Defective recombinant adenoviruses expressing cytokines for antitumor treatment9US 7,306,793 B2Centre National De La Recherche Scientifique · 2007
- Immortalized human cell lines containing exogenous cytochrome P450 genes7US 5,660,986 A1997